WO2012134168A2 - Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum - Google Patents

Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum Download PDF

Info

Publication number
WO2012134168A2
WO2012134168A2 PCT/KR2012/002276 KR2012002276W WO2012134168A2 WO 2012134168 A2 WO2012134168 A2 WO 2012134168A2 KR 2012002276 W KR2012002276 W KR 2012002276W WO 2012134168 A2 WO2012134168 A2 WO 2012134168A2
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
composition
extract
present
yeongneung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002276
Other languages
English (en)
Korean (ko)
Other versions
WO2012134168A3 (fr
Inventor
황성연
정경채
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Bio Medical Science Institute Co Ltd
Original Assignee
Korea Bio Medical Science Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Bio Medical Science Institute Co Ltd filed Critical Korea Bio Medical Science Institute Co Ltd
Publication of WO2012134168A2 publication Critical patent/WO2012134168A2/fr
Publication of WO2012134168A3 publication Critical patent/WO2012134168A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Definitions

  • the present invention relates to a novel use of Youngneung hyang extract. Specifically, the present invention relates to a therapeutic composition and a cosmetic composition containing Yeongneung-hyang extract as an active ingredient exhibiting excellent prophylactic or therapeutic efficacy against lung cancer.
  • lung cancer is a malignant tumor in the lung, and it can be divided into primary lung cancer, which is the first cancer cell in bronchial tissue, bronchiole, alveoli, etc. have.
  • Yeongreunghyang belongs to the Primaceae family and has been traditionally used as herbal medicines such as gamma headache, breast dressing, and roundworm disease. According to the research on the identification of Yeongneung flavor, compounds such as eugenol and methylchavicol have been reported.
  • the present inventors completed the present invention by confirming that the extract of Yeongneung-Hyang can effectively kill lung cancer cells during the study of herbal medicine for Yeongneung-Hyang.
  • the present invention provides a composition for the prevention and treatment of lung cancer comprising the active ingredient extracted Yeongneung flavor with an organic solvent.
  • the organic solvent is preferably ethanol.
  • the present invention provides a cosmetic composition for preventing lung cancer containing the yeongneunghyang ethanol extract containing an cosmetically acceptable cosmetic supplement additive as an active ingredient.
  • the present invention provides a composition for the prevention and treatment of lung cancer containing Yeongneung ethanol extract as an active ingredient.
  • the composition of the present invention includes Youngneung extract as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.
  • the lung cancer is preferably non-small cell lung cancer, wherein the non-small cell lung cancer is adenocarcinoma (adenocarcinoma), squamous cell carcinoma (squamous cell carcinoma) and large cell cancer ( More preferably caused by a carcinoma selected from the crowd consisting of large cell carcinoma.
  • adenocarcinoma adenocarcinoma
  • squamous cell carcinoma squamous cell carcinoma
  • large cell cancer More preferably caused by a carcinoma selected from the crowd consisting of large cell carcinoma.
  • lung cancer refers to a malignant tumor occurring in the lung, and includes both small cell lung cancer and non-small cell lung cancer such as adenocarcinoma, squamous cell carcinoma, and large cell lung cancer.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • composition for treating lung cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng, Gingseng, Liriopis Tuber, Poly
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as water for injection Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • Youngneung ethanol extract killed 99.8% of A549 non-small cell lung cancer cells at 100 ⁇ g / ml, and EC 50 (half maximal effective concentration) was 9.4 ⁇ g / ml.
  • the above results demonstrate that the Youngneung extract of the present invention has excellent killing activity of A549 non-small cell lung cancer cells and further has lung cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the development of lung cancer by administration of the composition.
  • treatment means any action that improves or advantageously changes the symptoms of lung cancer by administration of the composition.
  • Youngneung extract in the present invention can be extracted by using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the term “patient” refers to humans, horses, sheep, pigs, goats, camels, who have disease caused by lung cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means antelope, dog and other animals.
  • a composition comprising the extract of Yeongneung for the present invention, it is possible to effectively prevent and treat the above-mentioned lung cancer.
  • the composition of the present invention can be administered in parallel with existing lung cancer therapeutics.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.
  • the present invention provides a cosmetic composition for preventing lung cancer containing the yeongneunghyang ethanol extract containing an cosmetically acceptable cosmetic supplement additive as an active ingredient.
  • the cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the ethanol extract.
  • the cosmetic composition of the present invention is not particularly limited in the formulation, for example, it may have a flexible cosmetic water, nourishing cosmetics, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetic formulation, and also lotion, It may be a transdermal dosage form such as an ointment, gel, cream, patch or spray.
  • the Youngneung extract of the present invention inhibits the growth of lung cancer cells and induces apoptosis. Therefore, the composition for treating lung cancer according to the present invention will be very effective in the treatment of lung cancer patients.
  • A549 non-small cell lung cancer cells which are human lung cancer cells, wherein the X axis is the concentration of the extract of Youngneung, and the Y axis is alive. Survival rate of human lung cancer cells.
  • A549 cells, a lung cancer cell line used in the present invention were distributed from the Korean Cell Line Bank (KCLB) and used for experiments. Specifically, A549 lung cancer cells RPMI 1640 medium (Robwell Park Memorial) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subculture was performed in a floating culture medium researched and developed by the Institute.
  • KCLB Korean Cell Line Bank
  • Example 1 The Youngneung extract extracted in Example 1 was confirmed to inhibit the growth of lung cancer cells A549 non-small cell growth. Specifically, 1.4 X 10 per each well in a 96 well plate 3 Seeds of A549 lung cancer cells in dogs and incubated for 24 hours, then dissolved in DMSO (dimethyl sulfoxide) When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1).
  • Table 1 describes the relative cell numbers of lung cancer cells after 48 hours according to the concentration of each Yeongneung-based treatment based on the survival rate of lung cancer cells of the control group not treated with Yeongneung-dong.
  • the Youngneung extract of the present invention demonstrates excellent A549 non-small cell lung cancer cell killing activity, and further has lung cancer treatment and prophylactic activity.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally at a dose of 5 g / kg in suspension of the Youngneung extract of Example 1 of the present invention in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed, and autopsy was performed to observe abdominal and thoracic organ abnormalities.
  • the present inventors have confirmed that the lung cancer treatment effect of the Yeongneung-hyang extract through the above-mentioned excellent to prepare a lung cancer treatment containing the extract as an active ingredient as follows.
  • the preparation of the following therapeutic agents can be used for the application of not only therapeutic agents but also cosmetic compositions.
  • the present inventors confirmed that the Yeongneung-hyang extract is excellent in lung cancer treatment activity through the above embodiment to prepare a cosmetic composition containing it as an active ingredient as follows.
  • the nourishing cream was prepared by a conventional method according to the composition described below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'un extrait d'herbe de Lysimachia foenum-graecum et plus particulièrement, une composition pour le traitement du cancer du poumon et une composition pour des produits cosmétiques contenant, comme ingrédient actif, un extrait d'herbe de Lysimachia foenum-graecum ayant d'excellents effets prophylactiques et thérapeutiques sur le cancer du poumon. L'extrait d'herbe de Lysimachia foenum-graecum, selon la présente invention, élimine la prolifération des cellules cancéreuses dans le poumon et induit leur apoptose, et peut ainsi être utilisé efficacement dans la prophylaxie et le traitement du cancer du poumon.
PCT/KR2012/002276 2011-03-28 2012-03-28 Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum Ceased WO2012134168A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110027359A KR20120109138A (ko) 2011-03-28 2011-03-28 영릉향 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
KR10-2011-0027359 2011-03-28

Publications (2)

Publication Number Publication Date
WO2012134168A2 true WO2012134168A2 (fr) 2012-10-04
WO2012134168A3 WO2012134168A3 (fr) 2013-03-07

Family

ID=46932120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002276 Ceased WO2012134168A2 (fr) 2011-03-28 2012-03-28 Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum

Country Status (2)

Country Link
KR (1) KR20120109138A (fr)
WO (1) WO2012134168A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190943A1 (fr) * 2022-03-30 2023-10-05 株式会社AutoPhagyGO Agent d'activation de purge automatique et agent d'extension de vie saine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100544024B1 (ko) * 1998-07-31 2006-04-21 주식회사 엘지생활건강 피부 미백용 조성물
CN100408084C (zh) * 2006-04-20 2008-08-06 朱国豪 一种治疗癌症肿瘤的土家族药物及其制备方法

Also Published As

Publication number Publication date
WO2012134168A3 (fr) 2013-03-07
KR20120109138A (ko) 2012-10-08

Similar Documents

Publication Publication Date Title
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
KR20120122407A (ko) 석곡 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20120092283A (ko) 합환피 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20130022724A (ko) 호로파 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120111765A (ko) 백두구 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
KR20120122405A (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20120092274A (ko) 애엽 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20130022737A (ko) 포도근 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20120092280A (ko) 천초근 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20120122425A (ko) 독활 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20120109138A (ko) 영릉향 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
KR20120109787A (ko) 소자 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
WO2012134251A2 (fr) Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
KR20120122409A (ko) 소자 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014077432A1 (fr) Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques
WO2012134170A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de racine de rubia
WO2012134165A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de semence de psoraleae
WO2012134163A2 (fr) Composition pour le traitement du cancer du poumon et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20130027064A (ko) 청피 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014069688A1 (fr) Composition pour traiter le cancer rénal et composition cosmétique contenant un extrait de graine de perilla
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
WO2012134167A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12764027

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12764027

Country of ref document: EP

Kind code of ref document: A2